Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

NCT05116800 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT05116800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Withdrawn
Start date
March 1, 2022
Completion date
August 31, 2030
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, bone sarcoma, ewing sarcoma of bone, high grade sarcoma, leiomyosarcoma, liposarcoma, myxofibrosarcoma, osteosarcoma, rhabdomyosarcoma, soft tissue sarcoma, spindle cell sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma